Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $15.4880, but opened at $14.7001. Terumo shares last traded at $15.21, with a volume of 67,929 shares trading hands.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. Zacks Research upgraded shares of Terumo from a "hold" rating to a "strong-buy" rating in a report on Tuesday, October 13th. Nomura raised shares of Terumo from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, the stock has an average rating of "Strong Buy".
Check Out Our Latest Analysis on Terumo
Terumo Stock Performance
The stock has a market cap of $22.39 billion, a price-to-earnings ratio of 21.38 and a beta of 0.77. The firm has a fifty day simple moving average of $14.99 and a 200 day simple moving average of $14.29. The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13.
Terumo (OTCMKTS:TRUMY - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.13. The company had revenue of $1.97 billion during the quarter, compared to analysts' expectations of $1.84 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%. As a group, sell-side analysts expect that Terumo Corp. will post 0.86 earnings per share for the current year.
About Terumo
(
Get Free Report)
Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells medical devices and healthcare products. Its offerings support hospitals, physicians and other healthcare providers across areas including cardiovascular care, interventional procedures, blood management, cell and gene therapies, and general medical care.
The company's products include catheters, guidewires, stents and other devices used in cardiovascular and endovascular procedures, as well as blood bags, apheresis systems, cell-processing technologies, infusion and injection products, and hospital equipment.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Terumo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terumo wasn't on the list.
While Terumo currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.